

Polydatin exerts anti-tumor effects against renal cell carcinoma cells via induction of caspase-dependent apoptosis and inhibition of the PI3K/Akt pathway [Retraction]

Jin Y-L, Xin L-M, Zhou C-C, Ren Y. *Onco Targets Ther*. 2018;11:8185–8195.

The Editor-in-chief and Publisher of *OncoTargets and Therapy* wish to retract the published article.

Concerns were raised about the possibility of image manipulation in the published article. The alleged image manipulation relates to:

- Figure 2B 786-O 80 μM and Caki-1 80 μM
- Figure 4A Bcl-xl 786-O and Caki-1.

The authors provided the raw data for the requested images; however, the Editor found the provided images were unsatisfactory and doubts were raised about the accuracy of several other figures used in the article. The Editor determined the findings and conclusions presented in the study were no longer supported. The authors institution was contacted for comment but no response was received.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

